Development of a multimodal predictive model using PET/CT radiomics and clinical data for preoperative assessment of lymphovascular invasion in gastric cancer

利用PET/CT放射组学和临床数据构建多模态预测模型,用于胃癌淋巴血管侵犯的术前评估

阅读:1

Abstract

OBJECTIVES: To develop and validate a multimodal predictive model combining positron emission tomography/computed tomography (PET/CT) radiomic features with clinical data for the preoperative assessment of lymphovascular invasion (LVI) in patients with gastric cancer (GC). METHODS: Between December 2017 and December 2022, 325 GC patients with pathologically confirmed LVI status were retrospectively enrolled. PET/CT scans were performed according to standard protocols, and 1,057 radiomic features were extracted from both imaging modalities following appropriate preprocessing. LASSO regression was used to select informative features for separate CT, PET, and combined PET/CT models. Key clinical variables - including age, maximum standardized uptake value, total lesion glycolysis, lymph node metastasis, and tumor grade - were integrated using multivariate logistic regression to construct a comprehensive predictive model. Model performance was assessed using ROC curve analysis. Diagnostic metrics - including AUC, sensitivity, specificity, accuracy, and Net Reclassification Improvement (NRI) - were calculated for each model. RESULTS: The CT, PET, and combined PET/CT models achieved AUCs of 0.823, 0.761, and 0.861, respectively. The final multimodal model integrating PET/CT radiomics with clinical data demonstrated superior performance, with an AUC of 0.904, specificity of 91.91% and sensitivity of 74.07%. Independent predictors of LVI included age, SUVmax, TLG, and lymph node metastasis. NRI analysis showed a 10.35% improvement in risk classification compared to the PET/CT radiomic model alone. CONCLUSIONS: The multimodal predictive model demonstrated excellent diagnostic accuracy for preoperative assessment of LVI in GC patients and may support individualized treatment planning and risk stratification. Prospective multicenter studies are needed to further validate its clinical utility.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。